Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 17;12:88. doi: 10.1186/s13148-020-00879-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — Targeting G9A decreased stemness and in vitro cell proliferation of tumor initiating cells (TICs) derived from NSCLC patients. a Basal level of G9A expression and corresponding H3K9Me2 level in tumor spheres of tumor-initiating cells (TICs) isolated from primary non-small lung cancer tissues determined by western blot. b G9A expression in FACS-sorted CD133⁺ and CD133⁻ cells in two TICs. c Expression level of CD133, and H3K9Me2 following G9A knockdown are shown. G9A knockdown resulted in decreased sphere forming (10X magnification) (d), and cell proliferation capacity (e) of TICs in vitro. Treatment of TICs with G9A inhibitor UNC0642 resulted in decreased sphere forming (× 10 magnification) (f) and cell proliferation (g) capacity in vitro. (For t test: *P < 0.05, **P < .01, and ***P < 0.001)